Technical Trend Overview and Price Movement
As of 09 Feb 2026, Gland Pharma’s share price closed at ₹1,844.25, slightly down by 0.30% from the previous close of ₹1,849.80. The stock traded within a range of ₹1,750.65 to ₹1,863.70 during the day, indicating some intraday volatility. The 52-week high stands at ₹2,130.00, while the 52-week low is ₹1,200.00, placing the current price closer to the upper end of its annual range but showing signs of consolidation.
The technical trend has shifted from mildly bullish to mildly bearish, signalling a cautious stance among traders and investors. This shift is particularly relevant given the stock’s recent outperformance relative to the Sensex, with a one-month return of 8.66% compared to the Sensex’s decline of 1.74%, and a year-to-date gain of 7.08% versus the Sensex’s 1.92% loss. Over the past year, Gland Pharma has delivered a robust 21.42% return, significantly outperforming the Sensex’s 7.07% gain.
MACD and Momentum Oscillators: Divergent Signals
The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture. On a weekly basis, the MACD remains mildly bullish, suggesting that short-term momentum still favours upward price movement. However, the monthly MACD has turned mildly bearish, indicating that longer-term momentum is weakening. This divergence between weekly and monthly MACD readings highlights a potential inflection point where short-term optimism may be tempered by longer-term caution.
The Relative Strength Index (RSI) further complicates the outlook. The weekly RSI is bearish, signalling that the stock may be experiencing downward pressure or is approaching oversold conditions in the short term. Conversely, the monthly RSI shows no clear signal, implying a neutral stance over the longer horizon. This lack of monthly RSI confirmation suggests that while short-term momentum is faltering, the broader trend remains undecided.
Moving Averages and Bollinger Bands: Signs of Consolidation
Daily moving averages have turned mildly bearish, reflecting recent price weakness relative to short-term averages. This shift suggests that the stock may be entering a phase of consolidation or mild correction after its recent gains. Meanwhile, Bollinger Bands on both weekly and monthly charts remain mildly bullish, indicating that volatility is contained and the stock price is still within a relatively stable trading range. The coexistence of bearish moving averages and bullish Bollinger Bands points to a market in balance, with neither buyers nor sellers dominating decisively.
Turnaround taking shape! This Small Cap from NBFC sector just hit profitability with strong business fundamentals showing up. Catch it before the major breakout happens!
- - Recently turned profitable
- - Strong business fundamentals
- - Pre-breakout opportunity
Additional Momentum Indicators: KST, Dow Theory, and OBV
The Know Sure Thing (KST) indicator reveals a split scenario: bearish on the weekly timeframe but bullish on the monthly. This suggests that while short-term momentum is weakening, the longer-term trend remains intact, providing some reassurance to investors with a longer investment horizon.
Dow Theory assessments on both weekly and monthly charts are mildly bullish, reinforcing the notion that the broader trend is still positive despite recent short-term setbacks. Similarly, On-Balance Volume (OBV) readings are mildly bullish across weekly and monthly periods, indicating that volume trends support the price action and that accumulation may be occurring.
Mojo Score and Market Capitalisation Insights
Gland Pharma currently holds a Mojo Score of 54.0, which corresponds to a Mojo Grade of Hold. This represents an upgrade from a previous Sell rating as of 02 Feb 2026, reflecting improved technical and fundamental assessments. The Market Cap Grade stands at 3, signalling a mid-tier market capitalisation relative to peers in the Pharmaceuticals & Biotechnology sector.
Despite the recent downgrade in technical trend to mildly bearish, the upgrade in Mojo Grade suggests that the stock’s overall quality and outlook have improved, warranting a neutral stance rather than outright avoidance.
Comparative Performance and Long-Term Returns
When benchmarked against the Sensex, Gland Pharma has demonstrated superior returns over multiple timeframes. Notably, the three-year return of 57.08% significantly outpaces the Sensex’s 38.13%, underscoring the company’s strong growth trajectory in the medium term. However, the five-year return of -19.66% contrasts sharply with the Sensex’s 64.75%, indicating a period of underperformance that investors should consider when evaluating long-term prospects.
The absence of a 10-year return figure for Gland Pharma limits the ability to assess very long-term performance, but the recent years’ data suggest a recovery and growth phase following earlier challenges.
Holding Gland Pharma Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaway: Navigating Mixed Signals
Gland Pharma’s recent technical developments present a nuanced picture for investors. The shift from mildly bullish to mildly bearish technical trend, combined with mixed signals from MACD, RSI, and moving averages, suggests a period of consolidation or mild correction may be underway. Short-term momentum indicators such as the weekly RSI and KST point to caution, while longer-term indicators including monthly MACD, Dow Theory, and OBV maintain a cautiously optimistic outlook.
Investors should weigh these technical signals alongside fundamental factors and sector dynamics. The pharmaceutical and biotechnology sector continues to be driven by innovation, regulatory approvals, and global health trends, which could provide catalysts for renewed momentum in Gland Pharma’s shares.
Given the current Mojo Grade of Hold and the recent upgrade from Sell, a balanced approach is advisable. Investors with a medium to long-term horizon may consider maintaining positions while monitoring for confirmation of trend reversals or further deterioration. Short-term traders might exercise prudence and look for clearer signals before initiating new positions.
Overall, Gland Pharma remains a stock with potential but one that requires careful technical and fundamental analysis to navigate the evolving market conditions effectively.
Unlock special upgrade rates for a limited period. Start Saving Now →
